Dose Adjustments of Hydrocortisone and L-thyroxine in Hypopituitarism Associated with Cholestasis

A patient with congenital hypopituitarism associated with cholestasis is reported here. Large doses of fat-soluble hormones (hydrocortisone (20 mg/m(2)/day) and L-thyroxine (14 μg/kg/day)) were needed to resolve hypoglycemia and hypothyroidism during cholestasis. The doses could be reduced to 10 mg/...

Descripción completa

Detalles Bibliográficos
Autores principales: Higuchi, Asako, Hasegawa, Yukihiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Japanese Society for Pediatric Endocrinology 2006
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4004839/
https://www.ncbi.nlm.nih.gov/pubmed/24790327
http://dx.doi.org/10.1297/cpe.15.93
_version_ 1782314017665056768
author Higuchi, Asako
Hasegawa, Yukihiro
author_facet Higuchi, Asako
Hasegawa, Yukihiro
author_sort Higuchi, Asako
collection PubMed
description A patient with congenital hypopituitarism associated with cholestasis is reported here. Large doses of fat-soluble hormones (hydrocortisone (20 mg/m(2)/day) and L-thyroxine (14 μg/kg/day)) were needed to resolve hypoglycemia and hypothyroidism during cholestasis. The doses could be reduced to 10 mg/m(2)/day and 3.5 μg/kg/day, respectively, after improvement of cholestasis. Sodium valproate, which is a water-soluble drug, did not need any dose adjustments during cholestasis. Adjustment of fat-soluble hormone doses during cholestasis should be considered in patients with cholestasis.
format Online
Article
Text
id pubmed-4004839
institution National Center for Biotechnology Information
language English
publishDate 2006
publisher The Japanese Society for Pediatric Endocrinology
record_format MEDLINE/PubMed
spelling pubmed-40048392014-04-30 Dose Adjustments of Hydrocortisone and L-thyroxine in Hypopituitarism Associated with Cholestasis Higuchi, Asako Hasegawa, Yukihiro Clin Pediatr Endocrinol Original Article A patient with congenital hypopituitarism associated with cholestasis is reported here. Large doses of fat-soluble hormones (hydrocortisone (20 mg/m(2)/day) and L-thyroxine (14 μg/kg/day)) were needed to resolve hypoglycemia and hypothyroidism during cholestasis. The doses could be reduced to 10 mg/m(2)/day and 3.5 μg/kg/day, respectively, after improvement of cholestasis. Sodium valproate, which is a water-soluble drug, did not need any dose adjustments during cholestasis. Adjustment of fat-soluble hormone doses during cholestasis should be considered in patients with cholestasis. The Japanese Society for Pediatric Endocrinology 2006-08-02 2006 /pmc/articles/PMC4004839/ /pubmed/24790327 http://dx.doi.org/10.1297/cpe.15.93 Text en 2006©The Japanese Society for Pediatric Endocrinology http://creativecommons.org/licenses/by-nc-nd/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial No Derivatives (by-nc-nd) License.
spellingShingle Original Article
Higuchi, Asako
Hasegawa, Yukihiro
Dose Adjustments of Hydrocortisone and L-thyroxine in Hypopituitarism Associated with Cholestasis
title Dose Adjustments of Hydrocortisone and L-thyroxine in Hypopituitarism Associated with Cholestasis
title_full Dose Adjustments of Hydrocortisone and L-thyroxine in Hypopituitarism Associated with Cholestasis
title_fullStr Dose Adjustments of Hydrocortisone and L-thyroxine in Hypopituitarism Associated with Cholestasis
title_full_unstemmed Dose Adjustments of Hydrocortisone and L-thyroxine in Hypopituitarism Associated with Cholestasis
title_short Dose Adjustments of Hydrocortisone and L-thyroxine in Hypopituitarism Associated with Cholestasis
title_sort dose adjustments of hydrocortisone and l-thyroxine in hypopituitarism associated with cholestasis
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4004839/
https://www.ncbi.nlm.nih.gov/pubmed/24790327
http://dx.doi.org/10.1297/cpe.15.93
work_keys_str_mv AT higuchiasako doseadjustmentsofhydrocortisoneandlthyroxineinhypopituitarismassociatedwithcholestasis
AT hasegawayukihiro doseadjustmentsofhydrocortisoneandlthyroxineinhypopituitarismassociatedwithcholestasis

Ejemplares similares